Zacks.com Announces That Nadine Wong Highlights the Following Stocks: Millennium, Telik, Dendreon, Amgen, Genzyme, and Chiron.Business Editors CHICAGO--(BUSINESS WIRE)--Oct. 21, 2003 Get ready for a steady stream of new approvals out of the biotech industry. Become part of the favorable long-term trends of the space by using Nadine Wong's extensive analysis and stock recommendations. Read about Millennium (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :MLNM), Telik (NASDAQ:TELK), Dendreon (NASDAQ:DNDN), Amgen (NASDAQ:AMGN), Genzyme (NASDAQ:GENZ), and Chiron (NASDAQ:CHIR CHIR Chiricahua National Monument (US National Park Service) ). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/ Here are the highlights from the Featured Expert column: For the biotechs, the sector is in the midst Adv. 1. in the midst - the middle or central part or point; "in the midst of the forest"; "could he walk out in the midst of his piece?" midmost of multiple new product launches, and Nadine Wong expects a steady flow of new approvals extending at least over the next several quarters. Earnings growth for the large-cap biotech names remains significantly greater than for the pharmaceutical industry and the overall S&P 500. In her small and mid cap industry, Wong's top picks remain Millennium (NASDAQ:MLNM), Telik (NASDAQ:TELK), Dendreon (NASDAQ:DNDN), Repligen (NASDAQ:RGEN), Abgenix (NASDAQ:ABGX) and Tularik (NASDAQ:TLRK). These biotechs represent attractive near-term trading opportunities as they each have a story yet to be unfolded. Moving forward to the large-cap biotechs, Wong expects FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Amgen's (NASDAQ:AMGN) Enbrel in rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. for a once a week dosing versus the same total weekly dose which is administered twice weekly on its October 23rd PDUFA PDUFA Prescription Drug User Fee Act of 1992 (USA) date. Amgen's share price has been weak lately, but Wong foresees it as a buying opportunity. After listening to Genzyme's (NASDAQ:GENZ) third quarter conference call, Wong is encouraged with Renagel's outlook. Genzyme could face additional competition with the anticipated approval of Shire's Fosrenol. Whatever noise is made of this event would be a modest negative for Genzyme and the commercial impact is more likely to be subdued. Back in the July 2003 report, Wong discussed Chiron's (NASDAQ:CHIR) ability to become a leading flu vaccine The flu vaccine is a vaccine to protect against the highly variable influenza virus. The annual flu kills an estimated 36,000 people in the United States. franchise, and with the pending flu season
adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. vaccine, Fluvirin. Stay abreast of the biotech industry's new product losses by using Nadine Wong's analysis and stock information by clicking: http://featuredexpert3bw.zacks.com/ About Zacks Featured Experts To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Recommendations from Featured Experts Highlighted in FREE Investment Newsletter The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail See Internet e-mail service. newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion